ARTICLE | Clinical News
Ibrance palbociclib regulatory update
January 12, 2015 8:00 AM UTC
FDA told Pfizer there is no plan for an Oncologic Drugs Advisory Committee meeting to discuss the NDA for Ibrance palbociclib in combination with letrozole for first-line treatment of estrogen recepto...